Alice Capogrosso Sansone1, Stefania Mantarro1,2, Marco Tuccori3,4, Elisa Ruggiero5, Sabrina Montagnani1, Irma Convertino6, Alessandra Marino1, Matteo Fornai1, Luca Antonioli1, Tiberio Corona5, Danila Garibaldi2, Corrado Blandizzi1,6. 1. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 2. Pharmaceutical Unit, Health District of Lucca, Lucca, Italy. 3. Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy. marco.tuccori@gmail.com. 4. Tuscan Regional Centre for Pharmacovigilance, Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Via Roma, 55, 56126, Pisa, Italy. marco.tuccori@gmail.com. 5. Pharmaceutical Unit, Health District of Pisa, Pisa, Italy. 6. Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy.
Abstract
INTRODUCTION: Certolizumab pegol (CZP), an anti-tumor necrosis factor PEGylated Fab' fragment of a humanized monoclonal antibody, is currently approved for treatment of some immune-mediated inflammatory diseases (IMIDs). To our knowledge, no systematic review and meta-analysis evaluating the overall safety profile of CZP has been performed. OBJECTIVE: The objective of this systematic review was to assess the adverse event (AE) patterns of CZP versus a control in patients with IMIDs. METHODS: A systematic literature search was performed using PubMed/MEDLINE, EMBASE, the Cochrane Library, and the FDA database for clinical trials up to March 2014. Eligible studies were those that compared the safety profile of CZP to a control group in patients with IMIDs. The following data were extracted: number of patients experiencing AEs, serious AEs (SAEs), adverse drug reactions (ADRs), withdrawals due to AEs, fatal AEs, infectious AEs and SAEs, upper respiratory tract infections, injection-site reactions, neoplasms, and tuberculosis. RESULTS: A total of 2023 references were identified and 18 randomized controlled trials were included. The main pooled risk ratios of CZP-treated versus control patients were as follows: AEs 1.09 (95% confidence interval, CI 1.04-1.14), SAEs 1.50 (95% CI 1.21-1.86), ADRs 1.20 (95% CI 1.03-1.39), infectious AEs 1.28 (95% CI 1.13-1.45), infectious SAEs 2.17 (95% CI 1.36-3.47), and upper respiratory tract infections 1.34 (95% CI 1.15-1.57). CONCLUSION: Safety data on CZP suggest an overall favorable tolerability profile, with infections being the most common AE. However, CZP-treated patients had a twofold higher risk of infectious SAEs than control patients. Large observational studies and data from national registries are needed to detect rare AEs, which might occur after long-term exposures to CZP.
INTRODUCTION:Certolizumab pegol (CZP), an anti-tumornecrosis factor PEGylated Fab' fragment of a humanized monoclonal antibody, is currently approved for treatment of some immune-mediated inflammatory diseases (IMIDs). To our knowledge, no systematic review and meta-analysis evaluating the overall safety profile of CZP has been performed. OBJECTIVE: The objective of this systematic review was to assess the adverse event (AE) patterns of CZP versus a control in patients with IMIDs. METHODS: A systematic literature search was performed using PubMed/MEDLINE, EMBASE, the Cochrane Library, and the FDA database for clinical trials up to March 2014. Eligible studies were those that compared the safety profile of CZP to a control group in patients with IMIDs. The following data were extracted: number of patients experiencing AEs, serious AEs (SAEs), adverse drug reactions (ADRs), withdrawals due to AEs, fatal AEs, infectious AEs and SAEs, upper respiratory tract infections, injection-site reactions, neoplasms, and tuberculosis. RESULTS: A total of 2023 references were identified and 18 randomized controlled trials were included. The main pooled risk ratios of CZP-treated versus control patients were as follows: AEs 1.09 (95% confidence interval, CI 1.04-1.14), SAEs 1.50 (95% CI 1.21-1.86), ADRs 1.20 (95% CI 1.03-1.39), infectious AEs 1.28 (95% CI 1.13-1.45), infectious SAEs 2.17 (95% CI 1.36-3.47), and upper respiratory tract infections 1.34 (95% CI 1.15-1.57). CONCLUSION: Safety data on CZP suggest an overall favorable tolerability profile, with infections being the most common AE. However, CZP-treated patients had a twofold higher risk of infectious SAEs than control patients. Large observational studies and data from national registries are needed to detect rare AEs, which might occur after long-term exposures to CZP.
Authors: William J Sandborn; Stefan Schreiber; Brian G Feagan; Paul Rutgeerts; Ziad H Younes; Ralph Bloomfield; Geoffroy Coteur; Juan Pablo Guzman; Geert R D'Haens Journal: Clin Gastroenterol Hepatol Date: 2011-05-13 Impact factor: 11.382
Authors: E H S Choy; B Hazleman; M Smith; K Moss; L Lisi; D G I Scott; J Patel; M Sopwith; D A Isenberg Journal: Rheumatology (Oxford) Date: 2002-10 Impact factor: 7.580
Authors: Edward Keystone; Désireé van der Heijde; David Mason; Robert Landewé; Ronald Van Vollenhoven; Bernard Combe; Paul Emery; Vibeke Strand; Philip Mease; Chintu Desai; Karel Pavelka Journal: Arthritis Rheum Date: 2008-11
Authors: R Fleischmann; J Vencovsky; R F van Vollenhoven; D Borenstein; J Box; G Coteur; N Goel; H-P Brezinschek; A Innes; V Strand Journal: Ann Rheum Dis Date: 2008-11-17 Impact factor: 19.103
Authors: V P Bykerk; J Cush; K Winthrop; L Calabrese; O Lortholary; M de Longueville; R van Vollenhoven; X Mariette Journal: Ann Rheum Dis Date: 2013-10-03 Impact factor: 19.103
Authors: Juan S Lasa; Pablo A Olivera; Stefanos Bonovas; Silvio Danese; Laurent Peyrin-Biroulet Journal: Drug Saf Date: 2021-03-05 Impact factor: 5.606